Replies to post #1223 on GTC Biotherapeutics (fka GTCB)

[mblimon]

"If shareholders had ANY SAY about share price, it would be at $100/share now. But, alas, shareholders do not determine pps."

Then who does? There have been more sellers than buyers of this stock during the last few years. The short position (.5 mln) does not justify the present low share price.

The sellers are either retail holders or large shareholders who have bought their shares in placements. The first group buys in the market, so GTCB has no direct influence over them.

But then the second group. How did GTCB time the placements, how did they screen the beneficiaries of the placements, how did they negotiate the conditions and the price, what did they do to find reliable long term investors? These are just a few of many more questions.
Management is responsible for that and the share price is what we have as reflection of the success of these placements.

I have not a mayor problem with the LFB-deal. However, I have a problem in voting yes for another 100 mln shares, because I don't think GTCB has so far done a good job in taking money out of the market.

[y3maxx]

ThomasS wrote

""BTW, do you really believe that $1.19 is justified? I didn't think so. It has little to do with confidence in management by the "Market," imo.""

I completely disagree thomass

investing 101

Its about qualified leadership imo, the CEO & CFO's recent track record include two questionable recent share deals without any plausable explanation to its stakeholders. They forecast there was enough cash on hand to last into /07 before the first July dilution. So much for guidance.

They have not put a single penny of their own skin at these cheap street share prices.

They believe shareholders have no right to question their request to print a 100% increase in new shares.

These CEO and especially the CFO are coming across more as unqualified business leaders and lacking common sense.

jmo